FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy

被引：7

作者：

Chen, Shimin ^{[1
,2
,3
]}

Lin, Jichun ^{[1
,2
,3
]}

Zhao, Jiaojiao ^{[1
,2
,3
]}

Lin, Qian ^{[1
]}

Liu, Jia ^{[4
]}

Wang, Qiang ^{[5
]}

Mui, Ryan ^{[6
]}

Ma, Leina ^{[1
,2
]}

机构：

[1] Qingdao Univ, Canc Inst, Dept Oncol, Affiliated Hosp, Qingdao, Peoples R China

[2] Qingdao Canc Inst, Qingdao, Peoples R China

[3] Qingdao Univ, Sch Basic Med, Qingdao, Peoples R China

[4] Qingdao Univ, Sch Pharm, Dept Pharmacol, Qingdao, Peoples R China

[5] Shandong Second Prov Gen Hosp, Oncol Dept, Jinan, Peoples R China

[6] Sparrow Hosp, Dept Gastroenterol, Lansing, MI USA

来源：

FRONTIERS IN ONCOLOGY | 2023年 / 13卷

基金：

中国国家自然科学基金;

关键词：

FBXW7; drug resistance; E3; ligase; cancer; immunotherapy; F-BOX PROTEINS; GASTRIC-CANCER; MESENCHYMAL TRANSITION; PROMOTES PROLIFERATION; CHEMO-RESISTANCE; CYCLIN-E; C-MYC; FBW7; DEGRADATION; EXPRESSION;

D O I：

10.3389/fonc.2023.1147239

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

FBXW7 (F-box and WD repeat domain containing 7) is a critical subunit of the Skp1-Cullin1-F-box protein (SCF), acting as an E3 ubiquitin ligase by ubiquitinating targeted protein. Through degradation of its substrates, FBXW7 plays a pivotal role in drug resistance in tumor cells and shows the potential to rescue the sensitivity of cancer cells to drug treatment. This explains why patients with higher FBXW7 levels exhibit higher survival times and more favorable prognosis. Furthermore, FBXW7 has been demonstrated to enhance the efficacy of immunotherapy by targeting the degradation of specific proteins, as compared to the inactivated form of FBXW7. Additionally, other F-box proteins have also shown the ability to conquer drug resistance in certain cancers. Overall, this review aims to explore the function of FBXW7 and its specific effects on drug resistance in cancer cells.

引用

页数：14

共 50 条

[1] FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies
Wang, Wanqing
Jiang, Kaipeng
Liu, Xue
Li, Ju
Zhou, Wenshuo
Wang, Chang
Cui, Jiuwei
Liang, Tingting
FRONTIERS IN PHARMACOLOGY, 2023, 14
[2] Recent Insight on Regulations of FBXW7 and Its Role in Immunotherapy
Xing, Liangliang
Xu, Leidi
Zhang, Yong
Che, Yinggang
Wang, Min
Shao, Yongxiang
Qiu, Dan
Yu, Honglian
Zhao, Feng
Zhang, Jian
FRONTIERS IN ONCOLOGY, 2022, 12
[3] The role of FBXW7 as a predictor of imatinib resistance for GIST
Wu, Xiyu
Iwatsuki, Masaaki
Baba, Hideo
Lou, Meiyue
Ishimoto, Takatsugu
Baba, Yoshifumi
Miyamoto, Yuji
CANCER SCIENCE, 2023, 114 : 1847 - 1847
[4] FBXW7: a critical tumor suppressor of human cancers
Yeh, Chien-Hung
Bellon, Marcia
Nicot, Christophe
MOLECULAR CANCER, 2018, 17
[5] FBXW7γ is a tumor-suppressive and prognosis-related FBXW7 transcript isoform in ovarian serous cystadenocarcinoma
Xu, Zhou
Zhuang, Lin
Wang, Xiaoyin
Li, Qianrong
Sang, Yan
Xu, Jiao
FUTURE ONCOLOGY, 2020, 16 (25) : 1921 - 1930
[6] Recent insight into the role of FBXW7 as a tumor suppressor
Yumimoto, Kanae
Nakayama, Keiichi I.
SEMINARS IN CANCER BIOLOGY, 2020, 67 : 1 - 15
[7] FBXW7: a critical tumor suppressor of human cancers
Chien-Hung Yeh
Marcia Bellon
Christophe Nicot
Molecular Cancer, 17
[8] FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
Xiao, Yi
Yin, Chunli
Wang, Yuli
Lv, Hanlin
Wang, Wenqing
Huang, Yurong
Perez-Losada, Jesus
Snijders, Antoine M.
Mao, Jian-Hua
Zhang, Pengju
MOLECULAR ONCOLOGY, 2018, 12 (06) : 883 - 895
[9] Role of FBXW7 in imatinib primary and secondary resistance to GIST
Iwatsuki, Masaaki
Wu, Xiyu
Baba, Hideo
CANCER SCIENCE, 2024, 115 : 1900 - 1900
[10] Mutation in the FBXW7 Tumor Suppressor Gene of a childlike Melanoma
Pfoehler, C.
Ugurel, S.
Sucker, A.
Krecke, N.
Becker, S.
Vogt, T.
Mueller, C.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 21 - 21

← 1 2 3 4 5 →